ProCE Banner Activity

Interpreting the Nuances of DOAC Therapies for Patients With NVAF: The Pharmacist’s Role

Clinical Thought

Cardiology pharmacists’ perspectives on the pharmacist’s role in screening for NVAF, access to DOAC therapies, and dosing nuances.

Released: April 13, 2022

Expiration: April 12, 2023

No longer available for credit.

Share

Faculty

Stephanie Dwyer Kaluzna

Stephanie Dwyer Kaluzna, PharmD, BCCP

Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago College of Pharmacy
Cardiovascular Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Chicago, Illinois

Kathleen A. Lusk

Kathleen A. Lusk, PharmD, BCPS, BCCP

Associate Professor
Vice Chair
Department of Pharmacy Practice
University of the incarnate Word Feik School of Pharmacy
San Antonio, Texas

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb and Pfizer Alliance.

Bristol Myers Squibb

Pfizer Alliance

Faculty Disclosure

Kathleen A. Lusk, PharmD, BCPS, BCCP, has no relevant conflicts of interest to report.